REPLIGEN CORP (RGEN)       173.87  +3.54 (+2.08%)

173.87  +3.54 (+2.08%)

US7599161095 - Common Stock - After market: 173.87 0 (0%)

REPLIGEN CORP173.87

NASDAQ:RGEN (12/8/2022, 3:30:01 PM)+3.54 (+2.08%)

After market: 173.87 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Life Sciences Tools & Services
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-01 2022-11-01/bmo Earnings (Next) 02-15 2023-02-15
Ins Owners 0.65% Inst Owners 91.55%
Market Cap 9.65B Shares 55.52M
PE 50.99 Fwd PE 48.23
Dividend Yield N/A Analysts 85.33
IPO 04-29 1986-04-29

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RGEN Daily chart

Company Profile

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The company is headquartered in Waltham, Massachusetts and currently employs 1,852 full-time employees. The firm's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins. The Filtration products are used in process development and process scale production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all monoclonal antibody (mAb) based drugs on the market.

Company Info

REPLIGEN CORP

Building 1, Suite 100, 41 Seyon Street

Waltham MASSACHUSETTS 02453

P: 17814499560.0

CEO: Tony J. Hunt

Employees: 1852

Website: https://www.repligen.com/

RGEN News

News Image7 days ago - Market News VideoRepligen (RGEN) Shares Cross Above 200 DMANews Imagea month ago - Market News VideoBullish Two Hundred Day Moving Average Cross - RGENNews Imagea month ago - Market News VideoRepligen Moves Up In Market Cap Rank, Passing Caesars EntertainmentNews Imagea month ago - Repligen CorporationRepligen Corporation to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...

News Imagea month ago - Repligen CorporationRepligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance

Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organicDelivers...

News Imagea month ago - Repligen CorporationRepligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands

WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement...

RGEN Twits

Here you can normally see the latest stock twits on RGEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example